Is Vanda Pharmaceuticals Inc (VNDA) overvalued? · rev $102.2M
Vanda Pharmaceuticals Inc (VNDA) is a biotechnology company listed on NASDAQ.
This page asks whether Vanda Pharmaceuticals Inc (VNDA) looks expensive on cached numbers — not a short thesis.
Latest reported VNDA revenue for 2026-06-30 was $102.2M. Net income was -$111.1M. Revenue was up 97.7% from 2026-03-31 to 2026-06-30. VNDA currently screens at market cap $358.4M.
VNDA currently screens at market cap $358.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next VNDA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the VNDA stock page for the full model, not this heading.
Not investment advice.